Abstract
Drug discovery comprises all the activities involved in transforming a compound from a drug candidate to a product approved for marketable form and gaining regulatory permission to market it for use in the target indication(s). Bioinformatics, as related to genetics and genomics, is a scientific subdiscipline that involves using software tools to collect, store, compare, analyze and understand biological data and information, such as DNA, RNA, or protein and amino acid sequences or annotations about those sequences. The various innovative approaches in drug discovery include gene sequencing strategies, the role of bioinformatics, tissue expression patterns for target validation, ultra-high-throughput screening for lead identification, biology and chemistry approaches for developability screens, and finally the selection of a candidate molecule for clinical development. The above methodologies are incorporated in this chapter in detail. The overall detail explicates the progression of molecular targets to novel therapeutics under a new paradigm for drug discovery. These details will be useful for researchers working in the domain of drug discovery and pharmacoinformatics and eventually may help bring more effective drugs to patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agilent (n.d.). http://www.genomics.agilent.com/. Assessed 22 July 2022
Al-Salhi R, Abdul-Sada A, Lange A et al (2012) The xenometabolome and novel contaminant markers in fish exposed to a wastewater treatment works effluent. Environ Sci Technol 46:9080–9088
Anderson AC (2003) The process of structure-based drug design. Chem Biol 10:787–797
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683
Bennett CF (2019) Therapeutic antisense oligonucleotides are coming of age. Ann Rev Med 70:307–321
Bentley DR, Balasubramanian S, Swerdlow HP et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53–59
Bioconductor (n.d.) Open-Source Software for Bioinformatics. http://www.bioconductor.org/packages/2.9/bioc/html/goseq.html. Assessed 22 July 2022.
Blass BE (2015) Basic principles of drug discovery and development. Academic, New York, NY
Boss A, Kolb A, Hofmann M et al (2010) Diffusion tensor imaging in a human PET/MR hybrid system. Investig Radiol 45:270–274
Burbaum J, Tobal GM (2002) Proteomics in drug discovery. Curr Opin Chem Biol 6:427–433
Casazza JP, Cale EM, Narpala S (2022) Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med 28:1022–1030. https://doi.org/10.1038/s41591-022-01762-x
Chemicalize(n.d.). http://chemicalize.org. Assessed 22 July 2022
Computational Biology and Informatics Laboratory (n.d.). http://www.gusdb.org. Assessed 22 July 2022
Cosentino U, Pitea D, Moro G (2009) Conformational behaviour determines the low-relaxivity state of a conditional MRI contrast agent. Phys Chem Chem Phy 11:3943–3950
Dale JW, Schantz MV (2007) From genes to genomes. Concepts and applications of DNA technology, 2nd edn. Wiley, London
David PC, Nanette JP (2013) DNA sequencing. In: Clark DP, Pazdernik NJ (eds) Molecular biology, 2nd edn. Academic, New York, NY, pp 227–247. ISBN 9780123785947.
Franks SJ, Weber JJ, Aitken SN (2014) Evolutionary and plastic responses to climate change in terrestrial plant populations. Evol Appl 7:123–139
Glick BR, Pasternak JJ, Patten CL (2010) Molecular biotechnology: principles and applications of recombinant DNA, 4th edn. ASM Press, Washington, DC
Goodman LS, Gilman A, Brunton LL et al (2006) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, NY
Grant GR, Manduchi E, Stoeckert CJ Jr (2007) Analysis and management of microarray gene expression data. Curr Protoc Mol Biol 77:19–26
Gross S, Piwnica-Worms D (2006) Molecular imaging strategies for drug discovery and development. Curr Opin Chem Biol 10:33–342
Hartman KB, Laus S, Bolskar RD et al (2008) Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano Lett 8:415–419
Hoover R, Hunt T, Benedict M et al (2016) Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther 38:39–52. https://doi.org/10.1016/j.clinthera.2015.10.016
Hwang TJ, Kesselheim AS (2016) Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies. Health Aff 35:219–226. https://doi.org/10.1377/hlthaff.2015.1073
Jaffer FA, Libby P, Weissleder R (2009) Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol 29:1017–1024
Johanna K, Stefano D (2011) Disease gene identification: methods and protocols. Springer, New York, NY
Kalimuthu S, Jeong JH, Oh JM (2017) Drug discovery by molecular imaging and monitoring therapy response in lymphoma. Int J Mol Sci 18:1639
Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238–248
Krogsgaard-Larsen P, Liljefors T, Madsen U (2004) Text book of drug design and discovery, 3rd edn. Taylor & Francis, London
Kubinyi H, Folkers G, Martin YC (1998) 3D QSAR in drug design: recent advances, vol 3. Kluwer Academic Publishers, Norwell, MA
Kuehnbaum NL, Britz-McKibbin P (2013) New advances in separation science for metabolomics: resolving chemical diversity in a post-genomic era. Chem Rev 113:2437–2468
Kumar V, Sanseau P, Simola DF et al (2016) Systematic analysis of drug targets confirms expression in disease-relevant tissues. Sci Rep 6:36205
Kummar S, Rubinstein L, Kinders R et al (2008) Phase 0 clinical trials: conceptions and misconceptions. Cancer J 14:133–137. https://doi.org/10.1097/PPO.0b013e318172d6f3
Kyoto Enclyclopedia of Genes and Genomes (n.d.). http://www.genome.jp/kegg/. Assessed 22 July 2022
Larson RS (2006) Bioinformatics and drug discovery. Humana Press, Totowa, NJ
Lecchi M, Ottobrini L, Martelli C et al (2007) Instrumentation and probes for molecular and cellular imaging. Q J Nucl Med Mol Imaging 51:111
Leon D, Markel S (2006) In silico technologies in drug target identification and validation. Taylor & Francis, London
Lu Y, Machado HB, Bao Q (2011) In vivo mouse bioluminescence tomography with radionuclide-based imaging validation. Mol Imaging Biol 13:53–58
Mahan VL (2014) Clinical trial phases. Int J Clin Med 5:1374–1383
Marcotte R, Sayad A, Brown KR et al (2016) Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164:293–309
Martin YC (2010) Quantitative drug design: a critical introduction, 2nd edn. CRC, Boca Raton, FL
Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580
Michne WF (2010) Lead discovery: the process. In: Hit-to-lead process—lead compound discovery, milestone to new small molecule drug discovery. Wiley, New York, pp 1–19
Miggiels P, Wouters B, van Westen GJ (2019) Novel technologies for metabolomics: more for less. TRAC Trend Anal Chem 120:115323
Nagarajan K, Bodla RB (2018) Fundamentals principles of drug discovery. LAP Lambert Academic Publishing, Saarbruecken. ISBN: 9786139981441.
National Cancer Institute: Centre for Biomedical Informatics & Information Technology (n.d.). http://ncicb.nci.nih.gov/. Assessed 22 July 2022
Naz S, Vallejo M, GarcÃa A et al (2014) Method validation strategies involved in non-targeted metabolomics. J Chromatogr 1353:99–105
Ottobrini L, Ciana P, Biserni A (2006) Molecular imaging: a new way to study molecular processes in vivo. Mol Cell Endocrinol 246:69–75
Patrick GC (2001) An introduction to medicinal chemistry, 2nd edn. Oxford University Press, New Delhi
Patti GJ, Yanes O, Siuzdak G (2012) Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13:263–269
Pichler BJ, Wehrl HF, Judenhofer MS (2008) Latest advances in molecular imaging instrumentation. J Nucl Med 49(Suppl 2):5S–23S
Prejzendanc T, Wasik S, Blazewicz J (2016) Computer representations of bioinformatics models. Curr Bioinforma 11:551–560
Rankovic Z, Morphy R (2010) Lead generation approaches in drug discovery. Willey, Hoboken, NJ
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14:9–21
Rossi A, Gandolfo C, Morana G (2010) New MR sequences (diffusion, perfusion, spectroscopy) in brain tumours. Pediatr Radiol 40:999–1009
Rudin M (2009) Noninvasive structural, functional, and molecular imaging in drug development. Curr Opin Chem Biol 13:360–371
Shafiq N, Rajagopalan S, Kushwaha HN et al (2014) Single ascending dose safety and pharmacokinetics of CDRI-97/78: first-in-human study of a novel antimalarial drug. Malar Res Treat 2014:372521. https://doi.org/10.1155/2014/372521
Shendure J, Lieberman AE (2012) The expanding scope of DNA sequencing. Nat Biotechnol 30:1084–1094
Shoaib M, Singh A, Gulati S et al (2021) Chapter 8. In: Mapping genomes by using bioinformatics data and tools, chemoinformatics and bioinformatics in the pharmaceutical sciences, 1st edn. Academic, New York, NY, pp 245–278, ISBN 9780128217481.
Slatko BE, Albright LM, Tabor S et al (2001) DNA sequencing by the dideoxy method. Curr Protoc Mol Biol 7:Unit7.4A. https://doi.org/10.1002/0471142727.mb0704as47
Soule MC, Longnecker K, Johnson WM et al (2015) Environmental metabolomics: analytical strategies. Mar Chem 177:374–387
Tanner GJ, Blundell MJ, Colgrave ML et al (2016) Creation of the first ultra-low gluten barley (Hordeum vulgare L.) for celiac and gluten-intolerant populations. Plant Biotechnol J 14:1139–1150
Teufel A, Krupp M, Weinmann A et al (2006) Current bioinformatics tools in genomic biomedical research (review). Int J Mol Med 17:967–973
Totowa H (2007) Target discovery and validation reviews and protocols: emerging molecular targets and treatment options, vol 2. Humana Press, Totowa, NJ, p XIV, 345
Van Norman GA (2019) Phase II trials in drug development and adaptive trial design. JACC Basic Transl Sci 4:428–437. https://doi.org/10.1016/j.jacbts.2019.02.005
Velde GV, Baekelandt V, Dresselaers TE et al (2009) Magnetic resonance imaging and spectroscopy methods for molecular imaging. Q J Nucl Med Mol Imaging 53:565
Viant MR (2007) Metabolomics of aquatic organisms: the new ‘omics’ on the block. Mar Ecol Prog Ser 332:301–306
Virtual Computational Chemistry Laboratory (n.d.). www.vcclab.org/lab/alogps/. Assessed 22 July 2022
Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452:580–589
Wouters OJ, McKee M, Luyten J (2020) Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323:844–853. https://doi.org/10.1001/jama.2020.1166
Zaidi H, Prasad R (2009) Advances in multimodality molecular imaging. J Med Phys 34:122
Zhou B, Zhou Z, Chen Y et al (2020) Plasma proteomics-based identification of novel biomarkers in early gastric cancer. Clin Biochem 76:5–10
Acknowledgments
All the authors are highly grateful to the Director Dr. (Col) A. Garg and Joint Director Dr. Manoj Goel from the KIET Group of Institutions for their continuous inspiration and support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Nagarajan, K., Goel, R., Ghai, R., Grover, P. (2023). Innovative Strategies in Drug Discovery and Pharmacoinformatics. In: Singh, P.P. (eds) Recent Advances in Pharmaceutical Innovation and Research. Springer, Singapore. https://doi.org/10.1007/978-981-99-2302-1_7
Download citation
DOI: https://doi.org/10.1007/978-981-99-2302-1_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-2301-4
Online ISBN: 978-981-99-2302-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)